STOCK TITAN
  1. Home
  2. Sec-filings
  3. MNOV
  4. [Form 4] MEDICINOVA INC Insider Trading Activity

MediciNova (MNOV) director Nicole Lemerond receives 44,500 stock options grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MediciNova Inc. director Nicole Lemerond received a grant of stock options covering 44,500 shares of common stock. The options have an exercise price of $1.36 per share and expire on June 22, 2036. They vest in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027, contingent on her continued service with the company.

Positive

  • None.

Negative

  • None.

Insights

Routine director option grant with multi-year vesting and fixed strike price.

Director Nicole Lemerond received 44,500 stock options in MediciNova Inc. with a $1.36 exercise price and a 2036 expiration. This is characterized as a grant or award, not an open-market purchase or sale.

The options vest in four equal tranches from September 2026 through June 2027, subject to continued service. Such time-based vesting aligns director incentives with longer-term company performance. No same-day sales or exercises are reported, and this filing shows 44,500 derivative securities held following the grant.

Insider Lemerond Nicole
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 44,500 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy) — 44,500 shares (Direct)
Footnotes (1)
  1. F1. The option vests in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027, subject to continued service with the Company.
Options granted 44,500 options Stock Option (Right to Buy) granted to director
Exercise price $1.36 per share Conversion or exercise price of granted options
Expiration date June 22, 2036 Option expiration for this grant
Shares underlying options 44,500 shares Underlying MediciNova common stock
Total derivative holdings after grant 44,500 options Total shares following transaction
First vesting date September 30, 2026 First of four equal vesting installments
Final vesting date June 30, 2027 Last of four equal vesting installments
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
exercise price financial
"conversion_or_exercise_price: 1.3600"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vests in four equal installments financial
"The option vests in four equal installments on September 30, 2026..."

FAQ

What did MediciNova (MNOV) director Nicole Lemerond receive in this Form 4 filing?
Nicole Lemerond received a grant of stock options covering 44,500 shares of MediciNova common stock. The options are a compensation-related award, not an open-market purchase, and give her the right to buy shares at a fixed exercise price in the future.

What is the exercise price and expiration date of Nicole Lemerond’s MediciNova options?
The granted stock options have an exercise price of $1.36 per share and expire on June 22, 2036. This means she can choose to buy MediciNova shares at $1.36 any time before expiration, once the options vest, if conditions are satisfied.

How do the MediciNova (MNOV) stock options granted to Nicole Lemerond vest?
The options vest in four equal installments: September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027. Vesting is subject to her continued service with MediciNova, encouraging longer-term alignment between her role as director and shareholder interests.

Is Nicole Lemerond buying or selling MediciNova (MNOV) stock in this Form 4?
She is not buying or selling shares on the open market. The Form 4 reports a grant of 44,500 stock options as compensation, categorized as a grant or award acquisition. No open-market purchases or sales of MediciNova common shares are disclosed in this filing.

How many MediciNova derivative securities does Nicole Lemerond hold after this option grant?
Following the reported transaction, the filing shows Nicole Lemerond holding 44,500 derivative securities, representing options to acquire MediciNova common stock. These options become exercisable only as they vest over the period from late 2026 through mid‑2027, assuming continued service conditions are met.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lemerond Nicole
(Last)(First)(Middle)
C/O MEDICINOVA, INC.
4275 EXECUTIVE SQUARE, SUITE 300
(Street)
LA JOLLA CALIFORNIA
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
MEDICINOVA INC [ MNOV ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$1.3606/23/2026A44,500 (1)06/22/2036Common Stock44,500$044,500D
Explanation of Responses:
1. The option vests in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027, subject to continued service with the Company.
/s/ Yuichi Iwaki, Attorney-in-Fact06/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR